CD274 and neoplasm: Following our immune markers in the model, this can be explained mechanistically by a time window of opportunity, for dTeff to actively accumulate in tumor tissue (as stimulated by a transient RT-induced immune modulation), given a background of temporarily reduced PD-L1 immuno-suppression (thanks to a prior, or concurrent anti-PD-(L)1 administration).